Holen Sie sich die Stockscreener-App
4.20
6.60%
0.26
Handel nachbörslich:
4.10
-0.10
-2.38%
Schlusskurs vom Vortag:
$3.94
Offen:
$3.92
24-Stunden-Volumen:
94,244
Relative Volume:
0.77
Marktkapitalisierung:
$36.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-19.09
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
-21.35%
1M Leistung:
-55.95%
6M Leistung:
-64.37%
1J Leistung:
-65.64%
1-Tages-Spanne:
$3.91
$4.44
1-Wochen-Bereich:
$3.76
$5.3291
52-Wochen-Spanne:
$3.76
$19.35
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Firmenname
Atossa Therapeutics Inc
Sektor
Branche
Telefon
206.588.0256
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
4.20 | 33.93M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2018-01-26 | Eingeleitet | Maxim Group | Buy |
Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten
Jobs Data: Is Atossa Therapeutics Incs growth already priced inJuly 2025 Price Swings & Stepwise Swing Trade Plans - baoquankhu1.vn
Atossa Therapeutics issues letter to shareholders highlighting 2025 accomplishments and 2026 outlook - marketscreener.com
Atossa Therapeutics Issues 2026 Outlook and Strategic Update - TipRanks
Atossa Therapeutics Issues Letter To Shareholders Highlighting 2025 Accomplishments And 2026 Outlook - TradingView
Atossa Therapeutics Issues 2026 Shareholder Letter Highlighting Key Developments - TradingView
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - PR Newswire
Can Atossa Therapeutics Inc. be recession proofJuly 2025 Momentum & Community Consensus Trade Signals - mfd.ru
Atossa Therapeutics launches research program for oral therapy in DMD - Traders Union
We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully - Yahoo Finance
Market Outlook: Is Atossa Therapeutics Inc part of any ETFWeekly Trading Summary & Weekly Momentum Picks - baoquankhu1.vn
Mammoth Energy sets March 6 call to review full-year 2025 results - Stock Titan
Atossa Therapeutics Maintains Strong Market Position for (Z)-End - GuruFocus
Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - Sahm
ATOS stock tumbles 32% — here’s what retail investors think of the reverse stock split - MSN
Atossa Genetics (NASDAQ:ATOS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split - Asianet Newsable
Atossa Genetics (NASDAQ:ATOS) Sets New 1-Year LowWhat's Next? - MarketBeat
Atossa Therapeutics (ATOS) enters reverse-split Monday as Nasdaq compliance clock tightens - TechStock²
Atossa Genetics Inc. (NASDAQ:ATOS) Short Interest Up 56.4% in January - MarketBeat
Aug PreEarnings: How volatile is SKYQ stockWeekly Market Summary & Weekly Market Pulse Updates - baoquankhu1.vn
Atossa Genetics (NASDAQ:ATOS) Shares Set to Reverse Split on Monday, February 2nd - MarketBeat
Can Atossa Therapeutics Inc. lead its sector in growthGap Up & Verified Swing Trading Watchlist - mfd.ru
Atossa Therapeutics, Inc.'s (NASDAQ:ATOS) Profit Outlook - simplywall.st
Risk Hedge: Can Adagene Inc. Depositary Receipt stock outperform in a bear market2025 Sector Review & Long-Term Safe Investment Plans - baoquankhu1.vn
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
Atossa Genetics Inc. (NASDAQ:ATOS) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 - PR Newswire
Atossa Therapeutics' Founder and CEO Steven Quay, M.D., Ph.D. Named One of The Top 50 Healthcare Technology CEOs of 2025 (2026-01-21) - Seeking Alpha
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy - BioSpace
Big Picture: Is Atossa Therapeutics Inc part of any ETF2025 Fundamental Recap & Reliable Price Breakout Signals - baoquankhu1.vn
Atossa Therapeutics (ATOS) Gains as FDA Grants Orphan Drug Statu - GuruFocus
ATOS Receives FDA Orphan Drug Designation for Duchenne Treatment - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z) - GuruFocus
Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen in Duchenne Muscular Dystrophy - Intellectia AI
Experimental DMD treatment from Atossa earns rare FDA orphan status - Stock Titan
Atossa Therapeutics (ATOS) Receives Orphan Drug Designation, Shares Rise 10% - Intellectia AI
Atossa Therapeutics (ATOS) Receives FDA Orphan Drug Designation, Shares Rise 13% - Intellectia AI
Why Did ATOS Stock Jump 10% In Pre-Market Today? - Asianet Newsable
Atossa Therapeutics (ATOS) Shares Rise 12% on Advancing (Z)-endoxifen Program - Intellectia AI
FDA Grants Orphan Drug Status to Atossa Therapeutics' (ATOS) Z-E - GuruFocus
What Wall Street predicts for Atossa Therapeutics Inc stock priceAnalyst Upgrade & AI Forecast Swing Trade Picks - Bộ Nội Vụ
Atossa Therapeutics targets breast cancer care breakthroughs - Traders Union
Atossa Therapeutics outlines strategy for lead (Z)-Endoxifen program - The Globe and Mail
Will Atossa Therapeutics Inc. (YAG2) stock beat revenue estimatesWalking Comfort Picks & HOKA buying tips before checkout - ulpravda.ru
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving Average – Here’s Why - Defense World
Atossa Genetics (NASDAQ:ATOS) Shares Cross Below 200 Day Moving AverageHere's Why - MarketBeat
Is Atossa Therapeutics Inc. stock in correction or buying zoneJuly 2025 Outlook & Community Verified Watchlist Alerts - Улправда
Will Atossa Therapeutics Inc. stock benefit from AI adoptionQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - Улправда
Will Atossa Therapeutics Inc. stock outperform growth indexesWeekly Stock Analysis & Verified Momentum Watchlists - Улправда
What margin trends mean for Atossa Therapeutics Inc. stockPortfolio Gains Summary & Safe Swing Trade Setups - Улправда
Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atossa Therapeutics Inc-Aktie (ATOS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Remmel H. Lawrence | Director |
Mar 26 '25 |
Buy |
0.70 |
10,000 |
7,000 |
10,257 |
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):